New Preclinical Data Demonstrate Two of Vaxart’s COVID-19 Vaccine Candidates Protect Against Omicron
03. Juni 2022 08:00 ET
|
Vaxart, Inc.
Results provide additional support for the cross-reactivity of Vaxart’s oral vaccine candidates SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today...
Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults
02. Juni 2022 08:30 ET
|
Vaxart, Inc.
Results support safety and immunogenicity of the vaccine candidate in the highly vulnerable elderly population Preliminary boost study data also reported Norovirus has been estimated to...
Vaxart to Participate at the Jefferies Global Healthcare Conference
02. Juni 2022 08:00 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, SVP and Chief...
Vaxart Announces the Publication of Studies in the Peer-Reviewed Journal Science Translational Medicine That Suggest Mucosal Immunization Could Decrease SARS-CoV-2 Transmission
19. Mai 2022 08:30 ET
|
Vaxart, Inc.
A preclinical study in hamsters showed both a decrease in infectious virus and in transmission Phase 1 data measuring cross-reactivity also included in the publication SOUTH SAN FRANCISCO, Calif.,...
Vaxart Provides Business Update and Reports First Quarter 2022 Financial Results
09. Mai 2022 17:46 ET
|
Vaxart, Inc.
Data from COVID-19 Phase II study and norovirus Phase IB study are expected in 2022 Ended the 1st Quarter with $157.0 million in cash, cash equivalents and marketable securities SOUTH SAN FRANCISCO,...
Vaxart to Present at World Vaccine Congress Washington 2022 on April 20
14. April 2022 08:30 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., April 14, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, will present at the World Vaccine...
Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2021 Financial Results
24. Februar 2022 16:05 ET
|
Vaxart, Inc.
Company begins 2022 with multiple active programs with data readouts expected this year Initial data from COVID-19 Phase II study expected in the first half of 2022 and data from several norovirus...
Vaxart’s S-Only COVID-19 Vaccine Candidate Produces Strong-Cross Reactive Mucosal and Systemic Immune Responses in Non-Human Primates
24. Februar 2022 08:30 ET
|
Vaxart, Inc.
Newly published data demonstrates substantial cross-reactivity against multiple variants of COVID-19 S-only candidate is believed to be the first to demonstrate robust neutralizing antibody responses...
Vaxart Appoints Edward Berg as Senior Vice President and General Counsel
14. Februar 2022 08:00 ET
|
Vaxart, Inc.
Pharmaceutical Industry Veteran Brings Broad Legal Expertise to Vaxart Senior Management Team SOUTH SAN FRANCISCO, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today...
Vaxart to Participate at the H.C. Wainwright BioConnect Virtual Conference
04. Januar 2022 08:00 ET
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, SVP and Chief...